Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,707.83 +1,458.62 (+2.14%) CMC Crypto 200
1,518.66 +30.11 (+2.02%)
VIR Jun 2024 10.000 call
| Previous close | 0.5400 |
| Open | 0.8000 |
| Bid | 0.8000 |
| Ask | 1.4000 |
| Strike | 10.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.7500 - 1.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 222 |
Business WireVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
SAN FRANCISCO, May 21, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data
Simply Wall St.Analysts Just Shipped A Stunning Upgrade To Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
Shareholders in Vir Biotechnology, Inc. ( NASDAQ:VIR ) may be thrilled to learn that the analysts have just delivered a...
ZacksWall Street Analysts Think Vir Biotechnology (VIR) Could Surge 188.65%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.7% in Vir Biotechnology (VIR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
